Among gliomas, grade IV GBM is the most frequent and aggressive astrocytic tumors and very difficult to treat due to the frequent mutations and dysfunctions of tumor suppressors or oncogenes such as EGFR, PDGFRA, PTEN, TP53, NF1, CDKN2A/B, and TERT promoter, and highly diffusive growth, which makes tumor resection challenging and contributes to rapid tumor recurrence [1]. Here, CDKN2A is linked to neoplasm.